Last reviewed · How we verify

Maraviroc (MVC) — Competitive Intelligence Brief

Maraviroc (MVC) (Maraviroc (MVC)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CCR5 antagonist. Area: Infectious Disease / Virology.

marketed CCR5 antagonist CCR5 (C-C chemokine receptor type 5) Infectious Disease / Virology Small molecule Live · refreshed every 30 min

Target snapshot

Maraviroc (MVC) (Maraviroc (MVC)) — National Institute of Allergy and Infectious Diseases (NIAID). Maraviroc blocks the CCR5 chemokine receptor on the surface of CD4+ T cells, preventing HIV from entering and infecting these immune cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Maraviroc (MVC) TARGET Maraviroc (MVC) National Institute of Allergy and Infectious Diseases (NIAID) marketed CCR5 antagonist CCR5 (C-C chemokine receptor type 5)
Maraviroc, Darunavir/r Maraviroc, Darunavir/r Catholic University of the Sacred Heart marketed Antiretroviral combination (CCR5 antagonist + protease inhibitor) CCR5 co-receptor (maraviroc); HIV protease (darunavir)
emtricitabine, darunavir/cobicistat, maraviroc emtricitabine, darunavir/cobicistat, maraviroc Giovanni Di Perri marketed Antiretroviral combination (NRTI + PI + pharmacokinetic booster + CCR5 antagonist) HIV reverse transcriptase, HIV protease, CYP3A4, CCR5 co-receptor
Sirolimus + Maraviroc Sirolimus + Maraviroc University of Maryland, Baltimore marketed mTOR inhibitor + CCR5 antagonist combination mTOR; CCR5
Maraviroc + Zidovudine/Lamivudine Maraviroc + Zidovudine/Lamivudine ViiV Healthcare phase 3 CCR5 antagonist + nucleoside reverse transcriptase inhibitors (NRTIs) CCR5 co-receptor; HIV reverse transcriptase
Maraviroc (Celsentri) Maraviroc (Celsentri) ANRS, Emerging Infectious Diseases phase 3 CCR5 antagonist CCR5 (C-C chemokine receptor type 5)
Celsentri® Celsentri® Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer phase 3 CCR5 antagonist CCR5

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CCR5 antagonist class)

  1. ANRS, Emerging Infectious Diseases · 1 drug in this class
  2. Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer · 1 drug in this class
  3. National Institute of Allergy and Infectious Diseases (NIAID) · 1 drug in this class
  4. Theratechnologies · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Maraviroc (MVC) — Competitive Intelligence Brief. https://druglandscape.com/ci/maraviroc-mvc. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: